Amgen (AMGN) Q3 2025 10-Q Quarterly Report
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Amgen (AMGN) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Amgen Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $9.56B for Q3 2025, up 12% YoY from $8.15B; driven by volume growth (+14%), offset by net selling price declines (-4%)
- • Operating margin 26.4% (Operating income $2.53B from $2.05B), net income margin 33.6% (Net income $3.22B from $2.83B) for Q3 2025
- • Best performing product: Repatha sales up 33% Q3 ($2.15B vs $1.62B); worst performing: ENBREL sales down 30% Q3 ($1.69B vs $2.30B)
- • Cash $9.4B as Sept 30, 2025 vs $12.0B Dec 31, 2024; Operating cash flow $8.36B YTD vs $6.72B prior year; capital expenditures $1.2B YTD vs $0.7B prior year
- • Near-term risks: tariff impacts increasing costs, pricing pressures from U.S. drug pricing reforms, ongoing tax litigation, biosimilar competition expected to erode Prolia and XGEVA sales
Risk Factors
- • New risk: July 31, 2025 MFN Executive Order and July MFN Letter impose potential US drug price mandates affecting Medicaid, Medicare, and commercial payers
- • Updated regulatory risk: IRA Medicare price setting extended to approx. 100 drugs by 2031, with ENBREL and Otezla prices lowered for 2026 and 2027 respectively
- • Legal/compliance risk: Complex US government price reporting errors risk substantial fines and enforcement actions, plus possible additional rebate payments
- • Market risk: State-level PDABs impose new Upper Payment Limits, e.g. Colorado’s ENBREL UPL effective 2027, potentially lowering drug pricing and access
- • Financial risk: Cash and investments subject to market volatility and insured limits exceeded at financial institutions, risking access delays on uninsured funds
Amgen Q3 2025 Quarterly FinancialsXBRL
Revenue
$9.6B
▲ +12.4% YoY▲ +4.1% QoQ
Net Income
$3.2B
▲ +13.6% YoY▲ +124.6% QoQ
Operating Margin
26.4%
▲ +236bp YoY▼ -250bp QoQ
Net Margin
33.7%
▲ +37bp YoY▲ +1805bp QoQ
ROE
33.4%
Total Assets
$90.1B
EPS (Diluted)
$5.93
▲ +13.4% YoY▲ +124.6% QoQ
Operating Cash Flow
$4.7B
▲ +31.2% YoY▲ +105.4% QoQ
Source: XBRL data from Amgen Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Amgen Quarterly Reports
Get deeper insights on Amgen
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.